Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Class IIa histone deacetylases (HDACs) are pleiotropic regulators of various differentiation pathways and adaptive responses. They form complexes with other co-repressors and can bind to DNA by interacting with selected transcription factors, with members of the Myocyte Enhancer Factor-2 (MEF2) family being the best characterized. A notable feature of class IIa HDACs is the substitution of tyrosine for histidine in the catalytic site, which has occurred over the course of evolution and has a profound effect on the efficiency of catalysis against acetyl-lysine. Another distinctive feature of this family of "pseudoenzymes" is the regulated nucleus-cytoplasm shuttling associated with several non-histone proteins that have been identified as potential substrates, including proteins localized in the cytosol. Within the complexity of class IIa HDACs, several aspects deserve further investigation. In the following, I will discuss some of the recent advances in our knowledge of class IIa HDACs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12383505 | PMC |
| http://dx.doi.org/10.3390/biom15081061 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stereotactic radiofrequency thermocoagulation selectively targeting the subiculum for mesial temporal lobe epilepsy -Treatment concept and preliminary results.
Clin Neurol Neurosurg
August 2025
Department of Neurosurgery, Niigata Seiro Hospital, 5968-2 Hasuno, Seiro-machi, KitaKanbara-gun, Niigata 957-0124, Japan.
Objective: The recently emerging laser interstitial thermal therapy is becoming a substitute treatment for mesial temporal lobe epilepsy (MTLE) due to its less invasiveness, but it offers lower seizure-free rates than traditional open surgery. Another less invasive stereotactic ablation surgery, that is radiofrequency thermocoagulation, is also an alternative surgical procedure. In particular, magnetic resonance imaging-guided stereotactic radiofrequency thermocoagulation (MRgSRFTC) has shown excellent seizure outcomes.
View Article and Find Full Text PDFDistribution for platelet antibody in patients with immune-mediated platelet transfusion refractoriness.
Hematology
December 2025
Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China.
Objectives: HLA Class I, HPA (Human platelet antigen), CD36 allo/isoantibodies, and platelet glycoprotein autoantibodies are the primary causes of immune-mediated platelet transfusion refractoriness (iPTR). Detecting these antibodies and selecting antigen-negative platelets for transfusion effectively manages iPTR, but large-scale data on platelet antibody distribution in the Chinese population are scarce.
Methods: From Jan 2021 to Dec 2023, 2073 patients with suspected iPTR underwent platelet cross-matching via solid-phase red blood cell adherence.
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial.
Exp Hematol Oncol
August 2025
Division of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Background: Over the past two decades, most cancer vaccines have failed to be developed clinically. The lack of efficient priming with specific tumor antigens and/or weak adjuvants may explain this poor success rate. MVX-ONCO-1, a personalized cell-based vaccine, combines inactivated autologous tumor cells and encapsulated allogeneic human cells genetically engineered to produce granulocyte-macrophage colony stimulating factor (GM-CSF).
View Article and Find Full Text PDFClinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry.
Circulation
August 2025
Department of Cardiology, Centre Cardiologique du Nord, Saint-Denis, France.
Background: Comprehensive knowledge of the clinical presentation, contemporary management, and outcomes on "allcomer" patients referred for mitral valve surgery (MVS) are critical to evaluate current practice and adherence to guidelines, understand selection biases, and inform key stakeholders on quality improvement.
Methods: MITRACURE is a large international retrospective registry of consecutive adult patients who underwent isolated or combined MVS for mitral regurgitation (MR) in France or Canada in 2019 with in-depth clinical and echocardiographic characterization. Patients operated on for isolated mitral stenosis or who had a prior mitral valve intervention were excluded.
Class IIa HDACs Are Important Signal Transducers with Unclear Enzymatic Activities.
Biomolecules
July 2025
Laboratory of Epigenomics, Department of Medicine, Università degli Studi di Udine, 33100 Udine, Italy.
Class IIa histone deacetylases (HDACs) are pleiotropic regulators of various differentiation pathways and adaptive responses. They form complexes with other co-repressors and can bind to DNA by interacting with selected transcription factors, with members of the Myocyte Enhancer Factor-2 (MEF2) family being the best characterized. A notable feature of class IIa HDACs is the substitution of tyrosine for histidine in the catalytic site, which has occurred over the course of evolution and has a profound effect on the efficiency of catalysis against acetyl-lysine.
View Article and Find Full Text PDF